The Importance of Team-Based Management and Patient Communication

Pembrolizumab plus axitinib also improves the overall response rate vs sunitinib alone among patients with clear cell renal cell carcinoma in the phase 3 KEYNOTE-426 trial.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Lenvatinib plus pembrolizumab generates no new safety signals among patients with advanced renal cell carcinoma in the phase 3 CLEAR study.

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

The combination is also associated with a manageable toxicity profile in the second and subsequent treatment lines for patients with advanced renal cell carcinoma.

Santosh Rao, MD, discusses ongoing and potential future research efforts aiming to maximize the benefits that patients with kidney cancer may derive from integrative oncology treatment techniques.